ArticleMammalian genome : official journal of the International Mammalian Genome Society2026
Integrated multi-omics and machine learning prioritize key immune genes for multiple sclerosis risk prediction.
Article in Mammalian genome : official journal of the International Mammalian Genome Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Multiple sclerosis (MS) is a complex autoimmune disease with strong genetic components, but its genetic mechanisms remain largely underexplored. We aimed to pinpoint causal genes and evaluate their utility for MS risk prediction. We integrated MS genome-wide association study summaries with brain-derived splicing quantitative trait loci (sQTLs) and expression quantitative trait loci (eQTLs) via summary-data-based Mendelian randomization (SMR) and colocalization analyses to identify potential causal genes. Weighted gene coexpression network analysis (WGCNA) of the E-MTAB-5151 dataset identified MS-associated gene modules. LASSO regression determined the core gene signature. GO and KEGG enrichment analyses, immune infiltration, and gene set enrichment analysis (GSEA) explored the biological relevance. Using an independent protein quantitative trait loci (pQTL) dataset, key genes were further validated for pQTL-MS associations. SMR identified 28 sQTL genes and 66 eQTL genes for MS, 23 and 51 of which passed the colocalization tests, respectively. WGCNA identified three MS-associated modules, and their intersection with SMR genes prioritized 23 key genes. Functional enrichment analysis of the module genes and SMR genes highlighted the consistent involvement of immune-related pathways in MS, including lymphocyte activation and NF-κB signalling. LASSO regression established a 10–gene signature (ACP2, IL7, MYNN, RGS1, SAE1, SP140, TRAF3, TSPAN31, TYMP, and ZC2HC1A) with high predictive accuracy (AUC = 0.983 in internal validation; AUC > 0.70 across three external datasets). Immune infiltration analysis revealed a consistent immune cell expression pattern, in which the expression of MS risk genes was positively associated with naive CD4+ T cells and resting mast cells, but negatively associated with activated mast cells. In contrast, MS protective genes exhibited the opposite pattern. Furthermore, the integration of the MS genome-wide association study statistics validated ZC2HC1A and TRAF3 at the protein level. GSEA further linked both genes to the Hedgehog signalling pathway. Integrating genomic, transcriptomic, and proteomic data, we identified candidate causal genes for MS with robust evidence. ZC2HC1A and TRAF3 have emerged as promising biomarkers and mechanistic candidates for MS. Future follow-up functional studies are warranted to elucidate their molecular roles in MS pathogenesis.
Indexed as
Identifiers
41772215What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.